industry | Total sales revenue at SDC for the quarter was $174.2 million, an increase of 62.7% year over year, and the company completed just over 90,000 unique aligner shipments, compared with 57,136 in the second quarter of last year. Align Technology posts $1 billion in sales Staying with orthodontics, leading clear aligner maker Align Technology fared better than SDC during the quarter, as it continued to break its own earnings records. The company sold $841 million worth of clear aligner trays during the period—a year-over-year increase of 181.9%—and its imaging systems and CAD/CAM ser- vices revenue was $169.8 million, a 214.7% year-over- year increase. Total sales therefore topped $1 billion for the first time. Compared with the first quarter of this year, the company’s clear aligner and imaging services rev- enue streams were up 11.6% and 20.0%, respectively. Clear aligner volume for the second quarter increased by 200.0% year over year to reach 665,600 cases, and clear aligner volume for teenagers increased by 156.3% to reach 181,000 cases. A look at the company’s regional figures shows that dentists in most regions provided Invisalign treatment to more patients in the second quarter of this year than they did in the quarterly periods before the pandemic. In the Americas region, case volume was up 260.7% year over year. International shipments were up 149.2%, and those in the Europe, Middle East and Africa region (EMEA) were up 265%, led by Iberia, the UK and Italy. In the Asia Pacific region, clear aligner volume increased by 50%, led by Japan, China, Australia and New Zealand. Straumann remarks on improved patient volumes in 2021 The results of another international player, Straumann Group, will give readers an impression of the state of global dental markets. In the EMEA region, total sales of CHF 230 million (€212.7 million) represented a 102% year-over-year increase, which Straumann credited to sales of premium and challenger implant brands, its orthodontics business, and strong sales in Germany, Iberia, France, the UK and Turkey. Straumann’s organic sales growth in North America decreased by 42% during the second quarter of 2020; this year, it increased by 135% to reach CHF 152 million. Sales in the Asia Pa- cific region rebounded by 63% in the period to reach CHF 103 million. In Latin America, where Brazil is the largest contributor to regional revenue, CHF 31 million in sales represented a year-over-year increase of 174.4%. Straumann’s total revenue for the second quarter was CHF 516 million. This represented a year-over-year in- crease of around 92%—in the comparable period last year, Straumann’s total revenue of CHF 248 million was down nearly 40%. The company published a half-yearly report at the close of the second quarter, and in the report, the company said that dental practices had been operating with “healthy patient flows throughout the first half of 2021”. “With the exception of Latin America, which is still in the eye of the storm, all of our regions report that more than 85% of dental practices are open”—Guillaume Daniellot, CEO Straumann Group Guillaume Daniellot, Straumann CEO, reminded analysts in a conference call: “When we held our last media con- ference three months ago, our industry was in lockdown. COVID-19 had cut our monthly revenue by 70%, and we were initiating measures to reduce our headcount and cost base in preparation for the economic recession that the pandemic is expected to trigger.” He added that the situation on the day of the latest media conference (12 August 2021) was more positive. “With the exception of Latin America, which is still in the eye of the storm, all of our regions report that more than 85% of dental practices are open. Correspondingly, between 85% and 100% of our facilities are open and our sales team are operating at similar levels. In short, both we and our cus- tomers are back to business.” Envista optimistic about continued recovery Sales at Envista Holdings in the second quarter were $740.1 million, an increase of 104.4% year over year. The close of the period marked four consecutive quar- ters of growth for Envista’s premium implant business— which achieved 90% core sales growth in the three- month period ended 30 June. Envista CEO Amir Aghdaei said during the company’s earnings call that Envista had seen solid demand for its infection prevention business, owing to the fact that en- hanced disinfection protocols are now the new normal. Aghdaei said: “We’re excited about the opportunities for a new CaviWipes 2.0 product. It features a two-minute universal contact time, shows efficacy against a broad CAD/CAM 2 2021 07